Meiji Yasuda Asset Management Co Ltd.
Position in ROIV — Roivant Sciences Ltd.
CIK 1491685
Tokyo, M0
Position in ROIV
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$368,126
+$79,991 QoQ
Shares Held
10,402
0.0% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#311
of 495 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ROIV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Meiji Yasuda Asset Management Co Ltd. holds $10,170,872 across 12 Biotechnology names. ROIV ranks #5 (3.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
12,740 | $6,328,340 | |
| 2 | INCY |
Incyte Corp
|
5,097 | $577,795 | |
| 3 | RPRX |
Royalty Pharma plc
|
8,098 | $454,054 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
7,780 | $445,171 | |
| 5 | ROIV |
Roivant Sciences Ltd.
This page
|
10,402 | $368,126 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
1,452 | $349,888 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,085 | $326,617 | |
| 8 | EXEL |
Exelixis, Inc.
|
5,818 | $316,557 |
All Filings in ROIV
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $368,126 | 10,402 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $288,135 | 10,402 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $218,171 | 10,054 | Shares | Defined | 2026-02-06 | |
| 2025-09-30 | $154,189 | 10,191 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $114,852 | 10,191 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $102,827 | 10,191 | Shares | Defined | 2025-05-16 | |
| 2024-12-31 | $123,990 | 10,481 | Shares | Defined | 2025-02-12 | |
| 2024-09-30 | $123,893 | 10,736 | Shares | Defined | 2024-11-13 | |
| No filing history on record for this holder in this stock. | ||||||